openPR Logo

Press Releases from Marinomed Biotechnologie GmbH (4 total)

Viennese biotech company Marinomed demonstrates the benefits of its patented Mar …

• Solubilization of the immunomodulator tacrolimus up to 200 times greater using Marinosolv® • Bioavailability in the eye up to 15 times higher under laboratory conditions when compared to commercially available alternative treatments • Findings published in the European Journal of Pharmaceutics and Biopharmaceutics • Clinical trial for Tacrosolv, a tacrolimus-based product candidate against allergic conjunctivitis, planned for 2019 Vienna, 28 November 2018 – Marinomed Biotech AG (Marinomed) – an established Viennese biopharmaceutical company

Marinomed Biotechnologie GmbH: New investment boosts global expansion / innovati …

Marinomed Biotechnologie GmbH will boost the successful expansion of its business activities with new investments. The Austrian investment fund "aws Mittelstandsfonds" is acquiring a share in the company and is providing significant financial means. The fund management was impressed with the successful international market entry of Marinomed's treatments for cold and influenza-like diseases. By further investing, the global roll-out of these products will be accelerated. At the same time, the

Marinomed Biotechnologie GmbH: French Nicox S.A. successfully bids for anti-vira …

Vienna – Marinomed Biotechnologie GmbH agreed to sell its promising anti-viral eye drop program to Nicox S.A. of France. The France-based international ophthalmic company acquires the entire program as well as all associated rights, data, contracts and information. In return Marinomed will receive up to € 5.3 Mio. The anti-viral eye drop program of Marinomed derives from the successful technology platform Mavirex® which exploits anti-viral effects of polymers from red

Marinomed Biotechnologie GmbH: Pharma Company Acquires Rights to Antiviral Produ …

MAVIREX® technology is the basis for five products against viral respiratory infections The rights to five medical products of the Viennese biotech company Marinomed have now been licensed to an international pharmaceutical company for the Chinese market. Besides three antiviral nasal sprays against common cold, influenza and colds in children, the deal also includes the two newest products from Marinomed: antiviral lozenges and a throat spray against viral throat infections.